An obesity outlook that names a winning drug — but never weighs the catch

IQVIA's 2026 obesity outlook leans on tirzepatide's superiority, yet four frontier models found it skips the catch: muscle loss, adherence churn, and class safety — plus a drug-class error repeated twice.